Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Tivic Health Systems, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACQUISITION CREATES ADDITIONAL NEAR-TERM REVENUE OPPORTUNITIES FROM NEWLY FORMED CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) SUBSIDIARY, VELOCITY BIOWORKS FINANCING LED BY 3I, LP INCLUDES $16M DEBT FINANCING FOR THE PURCHASE OF ASSETS AND UP TO $75M IN PREFERRED CONVERTIBLE EQUITY AVAILABLE FOR THERAPEUTICS COMMERCIALIZATION AND CORPORATE GROWTH INITIATIVES FREMONT, CA AND SAN ANTONIO, TX / ACCESS NEWSWIRE / DECEMBER 11, 2025 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A DIVERSIFIED THERAPEUTICS COMPANY, TODAY ANNOUNCED IT HAS ACQUIRED THE STRATEGIC MANUFACTURING AND DEVELOPMENT ASSETS OF SCORPIUS HOLDINGS, INC. AND IS LAUNCHING VELOCITY BIOWORKS, A WHOLLY OWNED SUBSIDIARY OF TIVIC, TO PROVIDE CONTRACT DEVELOPMENT AND MANUFACTURING SERVICES TO TIVIC AND OTHER COMPANIES. STRATEGIC ADVANTAGES OF THIS ACQUISITION AND THE FORMATION OF VELOCITY BIOWORKS INCLUDE: SECURES A ROBUST US-BASED MANUFACTURING SITE FOR TIVIC'S LEAD DRUG CANDIDATE ENTOLIMOD AS THE COMPANY MOVES TOWARDS A BIOLOGICS LICENSE APPLICATION (BLA) WITH THE U.S. FOOD & DRUG ADMINISTRATION.

TIVIC ACQUIRES READY-TO-SCALE CGMP MANUFACTURING AND DEVELOPMENT ASSETS TO ACCELERATE COMMERCIALIZATION OF ENTOLIMOD; TIVIC GROWTH BACKED BY $90M+ FINANCING PACKAGE

MEETING WITH RADIOLOGICAL AND NUCLEAR MEDICAL COUNTERMEASURES PROGRAM FREMONT, CA / ACCESS NEWSWIRE / NOVEMBER 18, 2025 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A LATE-STAGE THERAPEUTICS COMPANY, TODAY ANNOUNCED IT HAS SECURED AN EXCLUSIVE TECHWATCH MEETING WITH THE BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA)'S RADIOLOGICAL AND NUCLEAR MEDICAL COUNTERMEASURES PROGRAM STAFF. TIVIC LEADERSHIP WILL BE PRESENTING CLINICAL DATA ON ENTOLIMOD'S EFFECTS ON RADIATION-INDUCED INJURY AND ACUTE RADIATION SYNDROME (ARS), ITS PROGRESS ON MANUFACTURING READINESS AND THE PREPARATIONS IT HAS BEEN MAKING FOR A BIOLOGICS LICENSE APPLICATION, OR BLA.

TIVIC SECURES BARDA MEETING FOR ENTOLIMOD(TM) FOR ACUTE RADIATION SYNDROME

CONTINUES EXECUTION OF STRATEGIC TRANSFORMATION AND ADVANCEMENT OF BIOLOGICS PIPELINE FREMONT, CA / ACCESS NEWSWIRE / NOVEMBER 14, 2025 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A DIVERSIFIED IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND PROVIDED A BUSINESS UPDATE. "FOLLOWING OUR DISCUSSIONS AT THE MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM AND CONTINUED ENGAGEMENT WITH KEY GOVERNMENT AGENCIES, WE ARE ENCOURAGED BY THE INTEREST IN OUR LEAD PRODUCT CANDIDATE, ENTOLIMOD FOR ACUTE RADIATION SYNDROME (ARS), AS A MILITARY MEDICAL COUNTERMEASURE AND STOCKPILE DRUG," STATED TIVIC CEO, JENNIFER ERNST.

TIVIC REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

THE STUDY DEMONSTRATED THAT PERSONALIZING THE STIMULATION PARAMETERS TO EACH USER DRAMATICALLY ENHANCED AUTONOMIC EFFECTS FREMONT, CA / ACCESS NEWSWIRE / NOVEMBER 13, 2025 / TIVIC HEALTH SYSTEMS, INC. (NASDAQ:TIVC), A DIVERSIFIED IMMUNOTHERAPEUTICS COMPANY, ANNOUNCED TODAY IT HAS OPTIMIZED KEY DEVICE AND TREATMENT PARAMETERS INCLUDING FREQUENCY, AMPLITUDE, ELECTRODE POSITIONING, AND DURATION OF STIMULATION AS A RESULT OF ITS COLLABORATIVE STUDY WITH THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH AT NORTHWELL HEALTH. PHYSIOLOGICAL MEASUREMENTS TAKEN BEFORE, DURING, AND AFTER NCVNS TREATMENT FOUND THE FOLLOWING: PERSONALIZING THE FREQUENCY OF NCVNS STIMULATION TO EACH STUDY SUBJECT RESULTED IN A 46% INCREASE IN HEART RATE VARIABILITY, WHICH WAS 8.9X MORE EFFECTIVE THAN APPLYING THE SAME FREQUENCY TO ALL SUBJECTS THE OPTIMAL NCVNS FREQUENCY FOR EACH SUBJECT WAS FOUND TO BE DIFFERENT BETWEEN VISITS, INDICATING THE IMPORTANCE OF PERSONALIZING THE STIMULATION PARAMETERS BEFORE EACH TREATMENT CERTAIN PLACEMENT AND CONFIGURATIONS OF ELECTRODES WERE FOUND TO BE MORE EFFECTIVE THAN OTHERS, WITH SOME PLACEMENTS INCREASING HEART RATE VARIABILITY AND OTHERS MARKEDLY REDUCE HEART RATE VARIABILITY FOUR MINUTES OF NCVNS STIMULATION WAS SUFFICIENT TO DRIVE A LARGE INCREASE IN HEART RATE VARIABILITY AND WAS MORE EFFECTIVE THAN TWENTY MINUTES OF STIMULATION.

TIVIC HEALTH REPORTS FINDINGS OF CLINICAL OPTIMIZATION TRIAL OF NON-INVASIVE CERVICAL VAGUS NERVE STIMULATION (NCVNS)

FREMONT, CALIF.--(BUSINESS WIRE)--TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC), A DIVERSIFIED THERAPEUTICS COMPANY, TODAY ANNOUNCED IT IS EXPANDING ITS INTELLECTUAL PROPERTY PORTFOLIO WITH THE RECENT FILING OF TWO ADDITIONAL PATENT APPLICATIONS WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE. THE FIRST APPLICATION APPLIES TO TIVIC'S TLR5 AGONIST PORTFOLIO, WHICH INCLUDES ENTOLIMOD AND ENTOLASTA. THE PATENT TITLED IMMUNOMODULATORY PATHWAY MODIFYING AGENTS AND USES OF SAME FOR CANCER THERAPY R.

TIVIC EXPANDS INTELLECTUAL PROPERTY PORTFOLIO

FREMONT, CALIF.--(BUSINESS WIRE)--TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC), A DIVERSIFIED IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED THAT IT WILL REPORT ITS THIRD QUARTER RESULTS FOR 2025 VIA PRE-RECORDED CONFERENCE CALL AND WEBCAST ON FRIDAY, NOVEMBER 14, 2025 AT 1:30 PM PT / 4:30 PM ET. TELECONFERENCE DETAILS: TOLL FREE: 888-506-0062 INTERNATIONAL: 973-528-0011 PARTICIPANT ACCESS CODE: 230582 WEBCAST LINK HTTPS://WWW.WEBCASTER5.COM/WEBCAST/PAGE/2865/53145 ABOUT TIVIC HEALTH SYSTEMS, INC. T.

TIVIC HEALTH TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 14TH VIA CONFERENCE CALL AND WEBCAST

FREMONT, CALIF.--(BUSINESS WIRE)--TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC), A DIVERSIFIED IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED THAT CEO, JENNIFER ERNST, WILL PARTICIPATE IN THE EIGHTH ANNUAL CONSTELLATION FORUM, A GLOBAL CONVERSATION ON BIOELECTRONIC MEDICINE. SHE WILL JOIN OTHER LEADERS IN THE FIELD TO DISCUSS THE OPPORTUNITIES FOR ADVANCING BIOELECTRONIC MEDICINE. WHEN: THURSDAY, OCT. 23, AT 11:55 A.M. ET/8:55 A.M. PT PANEL TITLE: BUILDING A BIG TENT BIOELECTRONIC MEDICINE STANDS TO.

TIVIC CEO, JENNIFER ERNST, TO JOIN PANEL AT 8TH ANNUAL NORTHWELL HEALTH INNOVATION CONSTELLATION FORUM ON THURSDAY, OCT. 23

FREMONT, CALIF.--(BUSINESS WIRE)--TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC), A DIVERSIFIED IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED THAT THE COMPANY'S CEO WILL PRESENT DURING THE EMERGING GROWTH VIRTUAL CONFERENCE SET TO TAKE PLACE ON SEPTEMBER 24 & 25, 2025. WHO: JENNIFER ERNST, CHIEF EXECUTIVE OFFICER WHERE: SEPTEMBER 25, 2025 WHEN: 11:25AM - 11:55AM EASTERN TIME JENNIFER ERNST, CEO OF TIVIC, WILL DELIVER A FORMAL PRESENTATION DETAILING THE COMPANY'S STRATEGIC TRANSFORMATION INTO THE.

TIVIC HEALTH CEO JENNIFER ERNST TO PRESENT AT EMERGING GROWTH'S SEPTEMBER VIRTUAL CONFERENCE

FREMONT, CALIF.--(BUSINESS WIRE)--TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC), A DIVERSIFIED IMMUNOTHERAPEUTICS COMPANY, TODAY ANNOUNCED THAT IT HAS COMPLETED VERIFICATION OF ITS ENTOLIMOD CELL LINE, THE FIRST STEP IN ESTABLISHING CURRENT GOOD MANUFACTURING PRACTICES (CGMP) IN PREPARATION FOR A BIOLOGICS LICENSE APPLICATION, OR BLA. CELL LINE VERIFICATION IN RECOMBINANT PROTEIN PRODUCTION IS REQUIRED BECAUSE IT ENSURES THE PROCESSES USED TO GROW CELLS AND ACTIVATE PROTEIN EXPRESSION DO NOT COMP.

TIVIC COMPLETES VERIFICATION OF ENTOLIMOD CELL LINE: FIRST STEP IN ESTABLISHING CGMP MANUFACTURING FOR BLA FILING

FREMONT, CALIF.--(BUSINESS WIRE)--TIVIC HEALTH SYSTEMS, INC. (NASDAQ: TIVC), A DIVERSIFIED THERAPEUTICS COMPANY, IS PROUD TO ANNOUNCE IT ADVANCED DISCUSSIONS WITH KEY US GOVERNMENT AGENCIES THROUGH ITS PARTICIPATION IN THE 2025 MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM (MHSRS), HELD AUGUST 4-7, 2025, IN KISSIMMEE, FLORIDA. THE MHSRS IS THE DEPARTMENT OF DEFENSE'S PREMIER SCIENTIFIC MEETING THAT BRINGS TOGETHER MILITARY, ACADEMIC, AND INDUSTRY EXPERTS TO DISCUSS MEDICAL RESEARCH AND INNOVATION.

Tivic Health Systems, Inc.

TIVC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Tivic Health Systems, Inc.

TIVC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TIVC